secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0000950170-24-038429
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026
--------------------------------------------------------------------------------

- Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.
- Completed equity financing up to $110M; expects cash with Tranche B warrant exercise to fund operations into 2026.
- Phase 1 trial of SAB-142 for Type 1 diabetes on track for data by end of 2024.
- Appointed Michael G. King Jr. as CFO; Andrew Moin and Katie Ellias added to board.
- R&D expenses $16.5M (down from $36.4M); G&A $23.8M (up from $16.4M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/0000950170-24-038429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/sabs-20240329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer